Harrow, Inc. (HROW): Revenue
$272.30M
Year ended 2025-12-31
$275.59M
Trailing 12 months to 2026-06-30
+45.4%
3-year compound annual growth
+41.0%
5-year compound annual growth
+39.6%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $272.30M | +36.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $199.61M | +53.3% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $130.19M | +47.0% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $88.59M | +22.2% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $72.48M | +48.3% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $48.87M | -4.5% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $51.16M | +23.7% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $41.37M | +54.5% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $26.77M | +34.3% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $19.94M | +105.2% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $9.72M | +485.3% | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $1.66M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | $10.0K | n/a | 2015-03-12, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $272.30M | +36.4% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $268.77M | +170.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $268.09M | +60.4% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $262.60M | -0.3% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $255.87M | +23.3% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $291.85M | +43.7% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $296.15M | -15.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $297.18M | +11.6% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $247.00M | -4.3% |
Compare HROW, VREOF, LGND, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗